SIM
ATYR

Spark Investment Management’s aTyr Pharma ATYR Stock Holding History

Spark Investment Management’s Portfolio ATYR Stock Details ATYR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-1,657
Closed -$117K – 828
2017
Q3 		$117K Buy
+1,657
New +$76.8K 0.01% 650

Other funds holding ATYR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Spark Investment Management's ATYR Position: Q4 2017 in Review

Spark Investment Management sold out of aTyr Pharma (ATYR) in Q4 2017, closing a stake of 1,657 shares — an estimated $117K sold.

Spark Investment Management first reported a position in ATYR in Q3 2017 and held it in 1 quarter. The position peaked at $117K in Q3 2017. 41 funds tracked by Wall St. Rank hold ATYR as of Q4 2017.

  • Spark Investment Management reported no remaining aTyr Pharma position as of Q4 2017 after selling out during the quarter.
  • Spark Investment Management sold 1,657 aTyr Pharma shares in Q4 2017, an estimated $117K.
  • Spark Investment Management first reported a position in aTyr Pharma in Q3 2017 and held it in 1 quarter.
  • Spark Investment Management's aTyr Pharma position peaked at $117K in Q3 2017.
  • 41 funds tracked by Wall St. Rank held aTyr Pharma as of Q4 2017.

Based on Spark Investment Management's 13F filing for Q4 2017, filed 12 Feb 2018.